Patents by Inventor Jerry Nick
Jerry Nick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10689703Abstract: The present invention is related to novel methods for categorizing and treating subjects having Acute Respiratory Distress Syndrome (ARDS).Type: GrantFiled: April 26, 2016Date of Patent: June 23, 2020Assignee: National Jewish HealthInventors: Jerry A. Nick, Kenneth C. Malcolm
-
Patent number: 9624543Abstract: The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, HCA112, CSPG2, TLR2, and CD163.Type: GrantFiled: July 15, 2015Date of Patent: April 18, 2017Assignee: National Jewish HealthInventors: Milene Saavedra, Jerry Nick
-
Publication number: 20160312285Abstract: The present invention is related to novel methods for categorizing and treating subjects having Acute Respiratory Distress Syndrome (ARDS).Type: ApplicationFiled: April 26, 2016Publication date: October 27, 2016Inventors: Jerry A. Nick, Kenneth C. Malcolm
-
Patent number: 9314479Abstract: The invention relates to methods of inhibiting biofilm formation or reducing biofilms in a subject or on a device or surface by administering a charged compound such as a polyamino acid to a subject, device or surface. The invention also relates to compositions for inhibiting biofilm formation or reducing biofilms.Type: GrantFiled: May 5, 2015Date of Patent: April 19, 2016Assignee: National Jewish HealthInventors: Jerry A. Nick, Quinn M. Parks
-
Publication number: 20160068909Abstract: The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation.Type: ApplicationFiled: July 15, 2015Publication date: March 10, 2016Inventors: Milene Saavedra, Jerry Nick
-
Publication number: 20150366899Abstract: The invention relates to methods of inhibiting biofilm formation or reducing biofilms in a subject or on a device or surface by administering a charged compound such as a polyamino acid to a subject, device or surface. The invention also relates to compositions for inhibiting biofilm formation or reducing biofilms.Type: ApplicationFiled: May 5, 2015Publication date: December 24, 2015Inventors: Jerry A. Nick, Quinn M. Parks
-
Publication number: 20150010492Abstract: The invention relates to methods of inhibiting biofilm formation or reducing biofilms in a subject or on a device or surface by administering a charged compound such as a polyamino acid to a subject, device or surface. The invention also relates to compositions for inhibiting biofilm formation or reducing biofilms.Type: ApplicationFiled: May 1, 2014Publication date: January 8, 2015Applicant: National Jewish HealthInventors: Jerry A. Nick, Quinn M. Parks
-
Patent number: 8901167Abstract: Disclosed are compositions and methods for the inhibition of biofilm formation or reduction of existing or developing biofilms in a patient. These methods also inhibit the aggregation of bacteria that form biofilms in the airways. The methods include administering to a subject that has or is at risk of developing biofilms a compound or formulation that inhibits the formation or polymerization of actin microfilaments or depolymerizes actin microfilaments at or proximal to the site of biofilm formation. Such a compound can be administered in combination with a compound or formulation that inhibits the accumulation or activity of cells that are likely to undergo necrosis at or proximal to the site of biofilm formation (i.e., neutrophils). The methods and compositions can further include the use of anti-DNA and/or anti-mucin compounds, as well as other therapeutic compounds and compositions.Type: GrantFiled: October 12, 2012Date of Patent: December 2, 2014Assignee: National Jewish HealthInventors: Jerry A. Nick, Travis S. Walker, G. Scott Worthen
-
Patent number: 8753662Abstract: The invention relates to methods of inhibiting biofilm formation or reducing biofilms in a subject or on a device or surface by administering a charged compound such as a polyamino acid to a subject, device or surface. The invention also relates to compositions for inhibiting biofilm formation or reducing biofilms.Type: GrantFiled: February 14, 2008Date of Patent: June 17, 2014Assignee: National Jewish HealthInventors: Jerry A. Nick, Quinn M. Parks
-
Publication number: 20140005099Abstract: The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, HCA112, CSPG2, TLR2, and CD163.Type: ApplicationFiled: May 16, 2013Publication date: January 2, 2014Applicant: National Jewish HealthInventors: Milene Saavedra, Jerry Nick
-
Patent number: 8465923Abstract: The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, HCA 112, CSPG2, TLR2, and CD163.Type: GrantFiled: December 16, 2011Date of Patent: June 18, 2013Assignee: National Jewish HealthInventors: Milene Saavedra, Jerry Nick
-
Publication number: 20120149595Abstract: The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, HCA 112, CSPG2, TLR2, and CD163.Type: ApplicationFiled: December 16, 2011Publication date: June 14, 2012Applicant: National Jewish HealthInventors: Milene Saavedra, Jerry Nick
-
Patent number: 8101361Abstract: The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, HCA112, CSPG2, TLR2, and CD163.Type: GrantFiled: March 10, 2009Date of Patent: January 24, 2012Assignee: National Jewish HealthInventors: Milene Saavedra, Jerry Nick
-
Publication number: 20090233300Abstract: The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, HCA112, CSPG2, TLR2, and CD163.Type: ApplicationFiled: March 10, 2009Publication date: September 17, 2009Inventors: Milene Saavedra, Jerry Nick
-
Publication number: 20080207556Abstract: Disclosed are compositions and methods for the inhibition of biofilm formation or reduction of existing or developing biofilms in a patient. These methods also inhibit the aggregation of bacteria that form biofilms in the airways. The methods include administering to a subject that has or is at risk of developing biofilms a compound or formulation that inhibits the formation or polymerization of actin microfilaments or depolymerizes actin microfilaments at or proximal to the site of biofilm formation. Such a compound can be administered in combination with a compound or formulation that inhibits the accumulation or activity of cells that are likely to undergo necrosis at or proximal to the site of biofilm formation (i.e., neutrophils). The methods and compositions can further include the use of anti-DNA and/or anti-mucin compounds, as well as other therapeutic compounds and compositions.Type: ApplicationFiled: May 6, 2008Publication date: August 28, 2008Applicant: NATIONAL JEWISH MEDICAL AND RESEARCH CENTERInventors: Jerry A. Nick, Travis S. Walker, G. Scott Worthen
-
Publication number: 20080199509Abstract: The invention relates to methods of inhibiting biofilm formation or reducing biofilms in a subject or on a device or surface by administering a charged compound such as a polyamino acid to a subject, device or surface. The invention also relates to compositions for inhibiting biofilm formation or reducing biofilms.Type: ApplicationFiled: February 14, 2008Publication date: August 21, 2008Applicant: NATIONAL JEWISH MEDICAL AND RESEARCH CENTERInventors: Jerry A. Nick, Quinn M. Parks
-
Publication number: 20060030539Abstract: Disclosed are compositions and methods for the inhibition of biofilm formation or reduction of existing or developing biofilms in a patient. These methods also inhibit the aggregation of bacteria that form biofilms in the airways. The methods include administering to a subject that has or is at risk of developing biofilms a compound or formulation that inhibits the formation or polymerization of actin microfilaments or depolymerizes actin microfilaments at or proximal to the site of biofilm formation. Such a compound can be administered in combination with a compound or formulation that inhibits the accumulation or activity of cells that are likely to undergo necrosis at or proximal to the site of biofilm formation (i.e., neutrophils). The methods and compositions can further include the use of anti-DNA and/or anti-mucin compounds, as well as other therapeutic compounds and compositions.Type: ApplicationFiled: August 4, 2005Publication date: February 9, 2006Applicant: National Jewish Medical and Research CenterInventors: Jerry Nick, Travis Walker, G. Worthen